Parkinson's Disease Trial, Not Yet Recruiting NCT07480317 Sponsor: Jiangsu Province Nanjing Brain Hospital Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Not Yet Recruiting

NCT07480317
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with Parkinson's Disease based on the Movement Disorder Society's official diagnostic guidelines.
  • People whose Parkinson's Disease is rated as mild to moderate severity (Hoehn & Yahr Stage I–III).
  • People aged between 45 and 65 years.
  • People who are right-handed, whose Parkinson's medication has been stable for at least 1 hour before the brain scanning sessions, and who are able to keep their medication dosage the same throughout the 2-week treatment phase (unless a doctor determines a change is medically necessary).
  • People who are able to give informed consent themselves, or who have a legal guardian who can do so on their behalf.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who cannot have an MRI scan due to having certain implanted devices in their body, such as deep brain stimulation (DBS) electrodes, a heart pacemaker, or other metal implants.
  • People who have significant memory or thinking difficulties (based on a standard cognitive test score below 24) or who have severe psychiatric symptoms.
  • People who have a history of epilepsy or structural problems in the brain, such as significant brain shrinkage or disease affecting the brain's blood vessels.
  • People who have severe head tremors that would affect the quality of MRI scan images.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 86-13914725569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Jiangsu Province Nanjing Brain Hospital
Registry
ClinicalTrials.gov
Start date
20 March 2026
Est. completion
31 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) total score.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov